James River Group Holdings

JRVR · NASDAQ

$3.87+$0.01 (+0.26%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $3.86

JRVR analyst rating

HoldConsensus of 4 analysts over the last 12 months. 0% rate it a buy.

Strong buy0
Buy0
Hold4
Underperform0
Sell0

12-month price target · 4 analysts

Average $4.82 (+24.5% upside)

Low: $4.49
Now: $3.87
High: $5.25

Upgrades and downgrades

The latest rating actions, newest first

JRVR analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
UBS	Aug 17, 2026	Maintains	Neutral	$4.75 → $4.45	68%
Truist Securities	Aug 12, 2026	Maintains	Hold	$6.00 → $5.00	68%
UBS	May 19, 2026	Downgrade	Buy → Neutral	$8.00 → $4.75	68%
Citizens	May 5, 2026	Downgrade	Market Outperform → Market Perform	—	72%
Truist Securities	Mar 4, 2026	Maintains	Hold	$6.00 → $7.00	68%
Compass Point	Dec 16, 2025	Downgrade	Buy → Neutral	$7.00	55%

The case for and against

Updated Oct 16, 2026

Bull case

James River Group is supported by a focused strategy in the attractive U.S. E&S market, where management still sees positive casualty rate opportunities despite rising competition, social inflation, and elevated loss severity. Since CEO Frank D’Orazio’s arrival in 2021, the company has added stronger underwriting, claims, and ERM leadership, moved to tighter quarterly oversight, and maintained strong employee retention and growing submission activity, which should improve discipline and consistency. In 2Q, the E&S segment generated $250 million of gross written premiums and $137 million of net earned premiums, with a 65.2% accident year loss ratio and only $0.3 million of reserve strengthening, while the shift toward smaller insureds reflects a more selective, higher-quality mix.

Bear case

James River Group is viewed negatively because its latest results showed clear earnings and growth pressure, with adjusted 2Q operating EPS of $0.20 versus $0.24 expected, gross written premiums falling 29% to $269 million, and operating revenue down 8% to $160 million. The combined ratio of 100.2% and a 33.9% expense ratio suggest underwriting and cost discipline are not yet strong enough to offset volatility, while adverse reserve development remains a persistent risk in casualty E&S lines. Investor confidence is further weakened by the shrinking protection on adverse development reinsurance, with only $7.5 million remaining against a roughly $1 billion reserve base, making sustained upside difficult to justify.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.